Apollo Biowellness, Inc. Announces Exclusive Distribution Deal

Rhea-AI Summary

Apollo Biowellness (OTC Pink: KOAN) has secured an exclusive distribution agreement with Revive Regenerative, Inc. for its subsidiary Evolutionary Biologics' "Evo Bio" brand products across the United States and Canada. The distribution network includes plastic surgeons, dermatologists, med spas, and other healthcare providers.

The company anticipates significant growth in the last two quarters of 2025 and throughout 2026 as a result of this partnership. Apollo Biowellness also plans to pursue additional distribution agreements in Europe, Asia, and South America. This strategic move will allow Evolutionary Biologics to focus on developing new products and brands.

Revive Regenerative, recognized as a leader in the regenerative laser field, serves as an integrated supply chain provider for biologics and energy-based laser aesthetics, with a consumer products division established through strategic mergers and acquisitions.

Positive

• Secured exclusive distribution agreement for US and Canada markets
• Access to established network of medical professionals and facilities
• Company projects significant growth for Q3-Q4 2025 and 2026
• Strategic focus enabled for new product development
• Potential for additional international distribution agreements

Negative

• No specific revenue projections or financial terms disclosed
• Success dependent on distributor's performance

North Bergen, New Jersey--(Newsfile Corp. - July 1, 2025) - Apollo Biowellness, Inc. (OTC Pink: KOAN) (the "Company") announces that it has entered into an exclusive distribution sales agreement with Revive Regenerative, Inc., covering the United States and Canada for the distribution of its subsidiary Evolutionary Biologics products; the "Evo Bio" Brand. Revive Regenerative has distribution channels with Plastic Surgeons, Dermatologists, Med Spas and other providers. With the distribution agreement we expect significant growth for the last two quarters of 2025 and further significant growth in 2026.

Evolutionary Biologics Ad Campaign

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10533/257378_7eeedac234bb1a71_001full.jpg

The Company expects to enter into additional distribution agreements for other parts of the world, Europe, Asia, South America, etc. These distribution agreements will allow Evolutionary Biologics to concentrate on the development of additional products and brands.

You can follow and contact the Company on X at @ApolloBioKOAN.

James W. Zimbler, President, stated, "By entering into the exclusive distribution sales agreement with Revive Regenerative, and its experienced marketing and sales teams, we can expand the reach of Evo Bio and also concentrate on the development of exciting new products."

Revive Regenerative, Inc., is a leader in the regenerative laser field, and serves as the integrated supply chain backbone for biologics and energy-based laser aesthetics, and a consumer products division was formed through a series of strategic mergers, acquisitions and joint ventures.

About Apollo Biowellness, Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.

Before using any of our products, you should always consult with your veterinarian and/or family doctor.

Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.

Corporate Contact
James W. Zimbler
President/CEO/Director
info@evolutionarybiologics.com 
https://evobiologics.com/
631-806-1420

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257378

FAQ

What is the new distribution agreement announced by Apollo Biowellness (KOAN)?

Apollo Biowellness has signed an exclusive distribution agreement with Revive Regenerative for its Evo Bio brand products in the United States and Canada.

Which markets will the KOAN distribution agreement cover?

The agreement covers the United States and Canada, with plans to pursue additional distribution agreements in Europe, Asia, and South America.

What is the expected impact of the distribution deal on Apollo Biowellness (KOAN)?

The company expects significant growth in the last two quarters of 2025 and throughout 2026 as a result of the distribution agreement.

Who are the target customers for Apollo Biowellness's Evo Bio products?

The products will be distributed to plastic surgeons, dermatologists, med spas, and other healthcare providers through Revive Regenerative's network.

What is Revive Regenerative's role in the KOAN distribution agreement?

Revive Regenerative will serve as the exclusive distributor for Evolutionary Biologics' Evo Bio brand products, leveraging its position as a leader in regenerative laser field and integrated supply chain for biologics and aesthetics.